NewsMV
← News·MarketsMarkets

IOVA in focus: Iovance Biotherapeutics posts $99M second-quarter revenue, beats its own guidance by more than 10%

In focus for IOVA: an August 2026 corporate overview filed with the SEC shows Iovance Biotherapeutics generated approximately $99 million in second-quarter revenue, a print the company described as more than 10% above…

NM
NewsMV Markets Desk
3 min read
7 August 2026Markets desk
Share this dispatch
TickersIOVA
Categoryregulatory

Filed via sec.gov

← Back to all dispatchesFront page →
Keep reading

More from the markets desk

Markets · OutlookMarkets

Chinese biopharma shares rise on U.S. drug deal report

Chinese biopharma stocks rose on Monday after a report indicated the United States may continue to allow most drug licensing deals with Chinese firms. The move reflects a shift in expectations for regulatory access, a…

NM
NewsMV Markets Desk
3 min read
MarketsMarkets

PBoC holds benchmark lending rates steady for 16th month

The People's Bank of China has maintained its benchmark lending rates at current levels for the 16th consecutive month. The central bank’s decision to keep the cost of borrowing unchanged marks another month in a…

NM
NewsMV Markets Desk
3 min read
Markets · Digital AssetsMarkets

US Debt Hits $40T, But Bitcoin Correlation With Gold Remains Weak

The U.S. national debt reached $40 trillion in August, a figure that sparked a wave of bullish commentary for Bitcoin ($BTC). The narrative suggests that rising sovereign debt acts as a debasement trade, weakening the…

NM
NewsMV Markets Desk
3 min read